查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2099349

藥物釋放型支架：市場洞察、競爭格局與市場預測 - 2034 年

Drug-Eluting Stents - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

藥物釋放型支架市場概述

概述：

  • 2025年全球藥物釋放型支架市值27.9億美元，預計2034年將達到55.3億美元。
  • 在 2026 年至 2034 年的預測期內，市場預計將以 7.88% 的複合年成長率成長，這得益於心血管疾病發病率的上升、產品開發活動的活性化、文明病負擔的加重以及人們對微創治療的日益青睞。
  • 按類型分類，預計到 2025 年，冠狀動脈支架細分市場將佔藥物釋放型支架市場的 82%，從而推動市場成長。
  • 按支架類型分類，預計到 2025 年，鈷鉻合金支架將引領藥物釋放型支架市場，佔 46% 的市場佔有率。
  • 就塗層而言，預計到 2025 年，聚合物塗層細分市場將引領藥物釋放型支架市場，佔 68% 的市場佔有率。
  • 就藥物類型而言，預計到 2025 年，Everolimus司將引領藥物釋放型支架市場，佔 51% 的市佔率。
  • 按最終用戶分類，預計醫院領域將引領藥物釋放型支架市場，到 2025 年將佔 66% 的市場佔有率。
  • 2025 年，北美在藥物釋放型支架市場佔最大佔有率，達到 38%，但預計到 2034 年，亞太地區將實現最快成長。

藥物釋放型支架是一種小型可擴張管，在經皮導管治療過程中置入狹窄或阻塞的動脈中。支架表面塗覆有藥物，這些藥物會逐漸釋放到血管壁內，抑制導致血管再阻塞的細胞增生。該裝置由三個設計要素構成，市場也根據這三個要素進行分類。支架主體是一個金屬或聚合物平台，提供徑向支撐力並保持血管暢通。考慮到其強度、厚度和在螢光下的可見性，支架主體通常由鈷鉻合金、鉑鉻合金或鎳鈦合金製成。塗層是一種控制藥物釋放的載體。它包括聚合物系統，例如藥物洗脫後被吸收的可生物分解系統和不可生物分解的永久性系統，以及直接從支架表面釋放藥物以避免殘留聚合物引起潛在發炎反應的無聚合物系統。藥物本身是抗增殖劑，主要為利莫西林類藥物。其中，Everolimus應用最為廣泛，常與紫杉醇或其他藥物合併使用。藥物釋放型支架廣泛應用於冠狀動脈和周邊動脈，透過顯著降低支架內血管再阻塞和重組的需求，已基本取代了裸金屬支架。目前市場的特點是：支架材料正朝著超薄型、可生物分解聚合物和無聚合物設計方向發展；藥物塗層技術在周邊血管疾病治療中的應用日益廣泛；以及生物可吸收血管支架的出現。

藥物釋放型支架市場的主要市場促進因素

  • 全球心血管疾病負擔非常沉重，根據「世界心臟報告」，全球有超過 5 億人患有心血管疾病。
  • 冠狀動脈疾病的發生率很高；根據英國心臟基金會的「全球循環系統疾病概況介紹」，全球約有 2 億人患有冠狀動脈疾病。
  • 周邊動脈疾病非常常見；據美國心臟協會 (AHA) 稱，全球約有 2 億人患有周邊動脈疾病，「全球疾病負擔」研究報告稱，40 至 70 歲人群中有 5640 萬人患有此病。
  • 心房顫動及相關心血管疾病的負擔日益加重，美國心臟協會 (AHA) 估計，到 2030 年，全球將有超過 1,200 萬人患有心房顫動。
  • 糖尿病、肥胖、高血壓、血脂異常症等文明病的病例數量不斷增加，這會加速動脈硬化，並增加重組手術的需求。
  • 由於微創經經皮手術恢復期短、併發症發生率低，因此越來越受到人們的青睞，而開胸重組手術則逐漸被淘汰。
  • 各大廠商積極參與產品開發和法規核准工作，從而推動支架、塗層和藥物平台的更新換代。

推動藥物釋放型支架市場成長的因素

市場促進因素

心血管疾病發生率增加

藥物釋放型支架市場背後的根本驅動力是全球心血管疾病負擔的日益加重，這促使了大量重組手術的開展，而這些手術正是置入術整個藥物洗脫支架市場的基礎。根據「世界心臟報告」顯示，全球有超過5億人患有心血管疾病；英國心臟基金會的「世界循環系統疾病概況」指出，全球約有2億人患有冠狀動脈疾病，這是冠狀動脈支架植入術的主要適應症。美國心臟協會（AHA）估計，到2030年，全球將有超過1,200萬人患有心房顫動，這反映了心血管疾病的廣泛蔓延。此外，心血管疾病的負擔不僅限於冠狀動脈；美國心臟協會 (AHA) 報告稱，全球約有 2 億人患有周邊動脈疾病，而全球疾病負擔研究發現，40 至 70 歲人群中約有 5640 萬周邊動脈疾病病例。心血管疾病（慢性阻塞性肺病，COPD）盛行率的不斷上升直接且必然地推動了醫療器械的需求，因為冠狀動脈和外周循環阻塞的治療擴大採用經經皮導管血管重組而非開胸手術，而且大多數此類手術都會植入藥物釋放型醫療設備。隨著這些疾病在全球蔓延，對支架置入術等有效、微創治療方法的需求持續成長，使得心血管疾病負擔成為該市場最永續的成長要素。

文明病增加

全球與生活方式相關的代謝性疾病盛行率不斷上升，是藥物釋放型支架市場的重要促進因素。這些疾病會加速動脈粥狀硬化，導致需要重組的患者群體不斷擴大，患者往往更年輕。糖尿病、肥胖、高血壓、血脂異常症、缺乏運動和吸煙都會導致內皮損傷、發炎和斑塊形成，使冠狀動脈和周邊動脈狹窄。由於飲食結構的變化以及都市化過程中久坐生活方式的盛行，這些因素的綜合影響在已開發國家和開發中國家都在加劇。根據美國疾病管制與預防中心（CDC）統計，約47%的美國人至少有高膽固醇症、高血壓和吸菸這三大主要危險因子中的一種，這顯示即使在醫療體系完善的國家，這些潛在風險也十分普遍。糖尿病患者尤其容易發展為廣泛且快速進展的冠狀動脈疾病，且在治療後更容易發生血管再阻塞。這不僅增加了治療方案的數量，也提升了該領域特有的抗增殖藥物釋放型技術的臨床價值。心血管疾病不僅在老年族群中日益增多，在中年人口中也是如此，這顯著提高了對有效診斷和治療方法的需求。這推動了對創新技術的投資，並擴大了市場。代謝性疾病的盛行率是一個持續且日益惡化的全球趨勢，產生了巨大、結構性且不斷加速成長的需求。

市場限制因素

儘管藥物釋放型支架市場需求龐大且結構性擴張，但其成長速度和價值仍面臨許多限制因素。其中最重要的限制因素是支架本身存在的風險和併發症。雖然與裸金屬支架相比，藥物釋放型支架能顯著降低支架內血管再阻塞，但仍存在一些風險，例如晚期和極晚期支架血栓症（雖然罕見但往往致命，歷史上與耐用聚合物上內皮癒合延遲有關）、支架部位新生動脈粥樣硬化、支架斷裂或不匹配、支架植入過程中血管撕裂或穿孔以及再血管再阻塞這些風險使得患者需要長期服用雙聯抗血小板藥物，而雙聯抗血小板藥物本身也存在出血風險，這對於老年患者和接受抗凝血治療的患者而言尤其危險。因此，血栓形成風險和出血風險之間存在權衡，這限制了器械的選擇。產品召回和安全措施經常導致支架系統供應中斷，並損害了臨床醫生的信心。

第二個限制因素是嚴格的監理核准流程。這些植入式藥物-醫療設備組合的核准流程漫長而昂貴，需要大量的隨機臨床試驗數據，並接受美國食品藥物管理局（FDA）和歐盟醫療設備法規（MDR）等機構的上市後監管。這提高了市場進入門檻，延緩了市場准入，並將市場集中在具備合規能力的製造商手中。

第三個限制因素是嚴峻的價格壓力。冠狀動脈支架療法的成熟、低成本高產能製造商的湧入、印度等市場的國家價格上限以及中國基於銷量的採購計劃，都顯著壓低了平均售價，促使銷量成長速度日益超過價值成長速度。其他阻礙因素包括藥物釋放型球囊的競爭、針對特定患者的最佳藥物療法，以及進口零件和成品關稅造成的成本和供應波動。這些臨床、監管和經濟因素共同支撐著成長，但也導致不同細分市場和地區的發展進程存在差異。資料來源：同儕審查文獻、監管機構和公司資訊披露。

區域說明

北美洲

北美在銷售、創新和監管開拓方面處於主導，預計2025年將佔38%的市場。該地區的成長得益於多種因素的共同推動，包括冠狀動脈和周邊血管疾病的高發病率、先進的導管介入基礎設施、有利的保險報銷機制、高額的醫療費用支出，以及雅培、Medtronic、波士頓科學等公司的入駐。根據美國國立衛生研究院（NIH）統計，美國有2050萬人患有冠狀動脈疾病；美國疾病管制與預防中心（CDC）報告稱，每年有80.5萬例心肌梗塞；加拿大健康資訊研究所（CIHI）報告稱，有240萬加拿大人受到心臟病的影響。美國是新型支架、塗層和抗血小板藥物標籤檢視核准的基準市場。短期市場趨勢受超薄可生物分解聚合物平台、雙聯抗血小板治療持續時間縮短、向周邊血管區域擴張以及選擇性手術的門診性質等因素影響。

歐洲

歐洲是一個規模龐大且創新驅動的市場。德國、法國、義大利、英國和西班牙的人口老化顯著加重了冠狀動脈和周邊動脈疾病的負擔，而成熟的介入醫學實踐和國家醫療體系下普遍支持性的報銷制度也加劇了這個問題。歐洲製造商在可生物分解聚合物和無聚合物技術領域擁有卓越的創新能力，該地區往往是新平台的首發市場。一個典型的例子是用於治療股淺動脈病變的自膨脹藥物釋放型支架獲得了CE認證。儘管歐盟醫療設備法規加強了新核准所需的證據要求，並調整了產品供應結構以利於具備監管能力的製造商，但激烈的競標仍然對價格構成壓力。

亞太地區

亞太地區是成長最快的地區，其成長主要受人口老化加劇、冠狀動脈和周邊動脈疾病負擔迅速加重、糖尿病高發生率以及導管介入技術不斷提升等因素所驅動。政府對醫院和心臟中心的投資，尤其是在中國和印度，使得以往無法治療的疾病得以得到治療；同時，隨著國內實力雄厚的製造商提供具成本效益的醫療設備，醫療保健服務的可及性也在不斷提高。中國憑藉其大規模的國內產業，推動了銷售量的最大成長；日本受益於人口老化加劇、醫療技術進步以及高階產品的普及；而印度則蘊藏著巨大的長期發展機會。由於各國實施價格上限和批量採購政策，銷售價格受到擠壓，因此銷售成長速度超過了銷售額成長速度，但該地區所有細分市場的成長率均高於全球平均水平。

世界其他地區

「世界其他地區」包括中東、非洲和南美洲。這些地區在醫療保健服務取得方面存在顯著差異。在波灣合作理事會（GCC）成員國和南美大型市場（尤其是巴西），政府正加大對心臟導管介入基礎設施建設的投資，並擴大採用高階藥物釋放型裝置進行最新的經皮介入治療，使這些市場成為成長型市場。另一方面，在非洲許多地區，由於缺乏導管介入檢查室、訓練有素的介入醫療專業人員和必要的資金，冠狀動脈閉塞性疾病患者有很大一部分無法接受血管重建治療。在開發中國家，高品質器械的引進受到成本和保險報銷限制的限制。該地區的成長將受到以下因素的推動：對心臟醫療基礎設施的投資、心血管疾病負擔的日益加重、政府的醫療保健政策以及區域和亞洲製造商提供的低成本器械。

藥物釋放型支架市場的最新發展趨勢

2024年3月，波士頓科學公司宣布其AGENT藥物塗層球囊獲得美國食品藥物管理局（FDA）批准，用於治療冠狀動脈疾病患者的血管再阻塞。策略意義：美國首個獲準用於血管再阻塞的藥物塗層球囊解決了支架植入治療領域長期存在的難題：治療已植入支架內的再血管再阻塞。這拓展了抗增殖原則，使其發展成為一種「不留任何殘留物」的鄰近治療方法，既與再次植入支架形成互補，又與之競爭。

常問問題：

Q1.藥物釋放型支架市場的預期成長率是多少？

全球藥物釋放型支架市場預計在 2026 年至 2034 年的預測期內將以 7.88% 的複合年成長率成長。

Q2.藥物釋放型支架市場的目前規模和預期規模是多少？

2025年全球藥物釋放型支架市值27.9億美元，預計2034年將達到55.3億美元。

Q3.哪些地區正在推動藥物釋放型支架市場的發展？

預計2025年，北美將引領藥物釋放型支架市場，佔38%的市佔率。這主要歸因於冠狀動脈疾病和心肌梗塞的高發病率及其危險因素、先進的醫療基礎設施、有利的保險報銷機制，以及美國國立衛生研究院（NIH）和雅培公司的數據：美國有2050萬人患有冠狀動脈疾病；而根據美國疾病控制與預防中心（CDC）的數據，美國每年發生80.5萬例心肌梗塞。預計到2034年，亞太地區將達到最高的複合年成長率，這主要得益於人口老化、心血管疾病負擔加重以及中國、日本和印度導管介入治療能力的提升。

目錄

第1章：引言

  • 調查範圍
  • 市場區隔
  • 市場概覽

第2章：藥物釋放型支架：摘要整理

  • 主要亮點和市場概覽

第3章：影響藥物釋放型支架市場的關鍵因素

  • 市場促進因素
    • 心血管疾病發生率增加
    • 文明病增加
    • 人們越來越傾向微創手術
    • 產品開發和技術進步的活性化
  • 市場限制因素
    • 藥物釋放型支架相關的風險和併發症
    • 嚴格的法規核准流程
    • 價格壓力和競爭產品的替代
  • 市場機遇
    • 生物可吸收血管支架的開發
    • 將人工智慧和機器人技術應用於支架植入術

第4章 影響分析：人工智慧、地緣政治、貿易和經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：波特五力分析

  • 供應商的議價能力
  • 消費者議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭公司之間的競爭

第7章：藥物釋放型支架市場評估

  • 按類型
    • 冠狀動脈支架置入術
    • 周邊血管支架
  • 由 Scaffold 提供
    • 鉑金鉻
    • 鈷鉻合金
    • 鎳鈦諾
    • 其他
  • 按塗層類型
    • 聚合物基塗料
    • 無聚合物塗層
  • 依藥物類型
    • Everolimus
    • 紫杉醇
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 專科診所
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章：藥物釋放型支架市場的競爭格局

  • 競爭分析
  • 企業市場占有率分析（加值服務）

第9章：藥物釋放型支架市場的新創企業資金籌措與投資趨勢

第10章：公司簡介及產品介紹

  • Abbott Laboratories
    • 公司簡介
    • 公司簡介
    • 財務概覽
    • 產品列表
    • 策略舉措/熵
  • Medtronic plc
  • Boston Scientific Corporation
  • BIOTRONIK SE & Co. KG
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • B. Braun Melsungen AG
  • Meril Life Sciences Pvt. Ltd.
  • Biosensors International Group Ltd.
  • Lepu Medical Technology Co. Ltd.

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0231

Drug-Eluting Stents Market Summary

Overview:

  • The global drug-eluting stents market was valued at USD 2.79 billion in 2025 and is projected to reach USD 5.53 billion by 2034.
  • The market is expected to expand at a CAGR of 7.88% during the forecast period 2026-2034, supported by the increasing incidence of cardiovascular disorders, rising product development activity, the growing burden of lifestyle-related disease, and the increasing preference for minimally invasive procedures.
  • By type, the coronary stenting segment dominated the drug-eluting stents market with an 82% share in 2025.
  • By scaffold, the cobalt-chromium segment dominated the drug-eluting stents market with a 46% share in 2025.
  • By coating, the polymer-based coating segment dominated the drug-eluting stents market with a 68% share in 2025.
  • By drug type, the everolimus segment dominated the drug-eluting stents market with a 51% share in 2025.
  • By end-user, the hospitals segment dominated the drug-eluting stents market with a 66% share in 2025.
  • North America accounted for the largest share of the drug-eluting stents market at 38% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

A drug-eluting stent is a small expandable tube, placed within a narrowed or obstructed artery during a percutaneous catheter-based intervention, that is coated with a pharmacological agent released gradually into the vessel wall to inhibit the cellular proliferation responsible for restenosis. The device combines three engineered elements, and the market is organized upon them. The scaffold is the metallic or polymeric platform that provides radial strength and holds the vessel open, most commonly fabricated from cobalt-chromium, platinum-chromium, or nitinol alloys selected for their strength, thinness, and visibility under fluoroscopy. The coating is the carrier that governs the release of the drug, comprising polymer-based systems that may be biodegradable, resorbing after the drug has eluted, or non-biodegradable and permanent, alongside polymer-free systems that release the agent directly from the stent surface and avoid the inflammatory response that a retained polymer can provoke. The drug is the antiproliferative agent itself, principally the limus family, of which everolimus is the most widely used, together with paclitaxel and other agents. Applied across coronary and peripheral arterial territories, drug-eluting stents have largely displaced bare-metal stents by markedly reducing in-stent restenosis and the need for repeat revascularization. The contemporary market is defined by the movement toward ultrathin scaffolds and biodegradable-polymer and polymer-free designs, the expansion of drug-coated technology into peripheral disease, and the emergence of bioresorbable vascular scaffolds.

Drug-Eluting Stents Market Key Growth Drivers

  • A very large global cardiovascular disease burden, with the World Heart Report stating that over half a billion people were living with cardiovascular disease worldwide.
  • A high prevalence of coronary artery disease, with the British Heart Foundation Global Heart and Circulatory Diseases Factsheet reporting some 200 million people living with coronary artery disease worldwide.
  • A large peripheral artery disease population, with the American Heart Association reporting some 200 million people living with peripheral artery disease globally and the Global Burden of Disease study reporting 56.4 million prevalent cases among those aged 40 to 70.
  • A rising burden of atrial fibrillation and related cardiovascular conditions, with the American Heart Association estimating that over 12 million people will have atrial fibrillation globally by 2030.
  • Growing instances of lifestyle-related disorders, including diabetes, obesity, hypertension, and dyslipidemia, that accelerate atherosclerosis and the need for revascularization.
  • Increasing preference for minimally invasive percutaneous procedures over open surgical revascularization, offering shorter recovery and lower complication rates.
  • Rising product development and regulatory approval activity, refreshing scaffold, coating, and drug platforms across the leading manufacturers.

Key Companies in Drug-Eluting Stents Market

The competitive field is led by a small group of large medical technology companies operating full interventional cardiology franchises spanning scaffolds, coatings, and drug platforms, challenged by specialists in polymer-free and biodegradable-polymer technology and by cost-competitive regional manufacturers in Asia and Europe. The leading participants in the drug-eluting stents market include the following:

  • Abbott Laboratories
  • Medtronic plc
  • Boston Scientific Corporation
  • BIOTRONIK SE & Co. KG
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • B. Braun Melsungen AG
  • Meril Life Sciences Pvt. Ltd.
  • Biosensors International Group Ltd.
  • Lepu Medical Technology Co. Ltd.

Factors Contributing to the Growth of the Drug-Eluting Stents Market

Market Drivers

Increasing Incidence of Cardiovascular Disorders

The foundational driver of the drug-eluting stents market is the very large and rising global burden of cardiovascular disease, which generates the volume of revascularization procedures on which the entire category depends. The World Heart Report stated that over half a billion people were living with cardiovascular diseases globally, and the British Heart Foundation Global Heart and Circulatory Diseases Factsheet reported that some 200 million people are living with coronary artery disease worldwide, the principal indication for coronary stenting. The American Heart Association estimates that over 12 million people will have atrial fibrillation globally by 2030, reflecting the broader expansion of cardiovascular disease, and the burden extends beyond the coronary territory, with the American Heart Association reporting some 200 million people living with peripheral artery disease globally and the Global Burden of Disease study identifying 56.4 million prevalent cases of peripheral artery disease among those aged 40 to 70. Because obstructive atherosclerotic disease in both the coronary and peripheral circulations is increasingly managed through percutaneous catheter-based revascularization rather than open surgery, and because a drug-eluting stent is implanted in the great majority of these procedures, the rising prevalence of cardiovascular disorders translates directly and predictably into device demand. As these conditions become more widespread globally, the need for effective, minimally invasive treatments such as stenting continues to grow, making the cardiovascular disease burden the most durable driver of the market.

Growing Instances of Lifestyle-Related Disorders

The rising global prevalence of lifestyle-related metabolic disorders is a powerful driver of the drug-eluting stents market, because these conditions accelerate atherosclerosis and enlarge the population requiring revascularization, frequently at younger ages. Diabetes, obesity, hypertension, dyslipidemia, physical inactivity, and smoking each contribute to the endothelial injury, inflammation, and plaque formation that narrow the coronary and peripheral arteries, and their combined burden is climbing across both developed and developing economies as diets change and sedentary lifestyles spread with urbanization. The Centers for Disease Control and Prevention note that about 47% of Americans have at least one of the three principal risk factors of high blood cholesterol, high blood pressure, and smoking, illustrating how widely the underlying risk is distributed even in a well-resourced health system. Diabetic patients in particular develop more diffuse and rapidly progressive coronary disease and are more prone to restenosis after intervention, which increases both the volume of procedures and the clinical value of the antiproliferative drug elution that defines the category. Because cardiovascular disorders are rising among middle-aged individuals as well as the elderly, the demand for effective diagnostic and treatment options is increasing significantly, fueling investment in innovative technologies and expanding the market. As the metabolic-disease epidemic is a durable and worsening global trend, it provides a large, structural, and accelerating source of demand.

Market Restraints

Despite a large and structurally expanding demand base, the drug-eluting stents market faces material constraints that temper the pace and value of growth. The most significant is the risk and complications associated with the devices themselves. Although drug-eluting stents markedly reduce in-stent restenosis relative to bare-metal alternatives, they carry risks including late and very late stent thrombosis, a rare but frequently catastrophic event historically associated with delayed endothelial healing over durable polymers, as well as neoatherosclerosis within the stented segment, stent fracture or malapposition, vessel dissection or perforation during deployment, and restenosis that still occurs in a meaningful minority of cases, particularly in diabetic patients, small vessels, and long or complex lesions. These risks necessitate prolonged dual antiplatelet therapy, which itself carries a bleeding hazard that is especially problematic in elderly and anticoagulated patients, and the resulting trade-off between thrombotic and bleeding risk constrains device selection. Product recalls and safety actions affecting stent systems have periodically disrupted supply and eroded clinician confidence.

The second constraint is the stringent regulatory approval process. The pathway for these implantable, drug-device combination products is long, costly, and demanding of extensive randomized clinical evidence and post-market surveillance from authorities such as the United States Food and Drug Administration and the European Union Medical Device Regulation, which raises the barrier to entry, delays market access, and concentrates the market among manufacturers with regulatory scale.

The third constraint is severe pricing pressure. The maturity of coronary stenting, the entry of capable low-cost manufacturers, national price caps in markets such as India, and volume-based procurement programs in China have compressed average selling prices substantially, so that unit growth increasingly outpaces value growth. Additional constraints include competition from drug-coated balloons and from optimal medical therapy in selected patients, and the volatility that tariffs on imported components and finished devices add to cost and supply. Together, these clinical, regulatory, and economic factors ensure that growth, while structurally supported, proceeds unevenly across segments and geographies. Source: peer-reviewed literature; regulatory authorities; company disclosures.

Drug-Eluting Stents Market Segment Analysis

The global drug-eluting stents market is segmented by type (coronary stenting and peripheral stenting), by scaffold (platinum-chromium, cobalt-chromium, nitinol, and others), by coating (polymer-based coating, comprising biodegradable and non-biodegradable, and polymer-free coating), by drug type (everolimus, paclitaxel, and others), by end-user (hospitals, ambulatory surgical centers, and specialty clinics), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Type

Dominant Subsegment: Coronary Stenting.

Dominant: Coronary Stenting ~ 82%

The coronary stenting segment accounted for an 82% share of the drug-eluting stents market in 2025. Coronary stenting dominates the type structure because coronary artery disease is the largest single indication for percutaneous revascularization and because the drug-eluting stent originated in and remains overwhelmingly concentrated in the coronary circulation. The British Heart Foundation Global Heart and Circulatory Diseases Factsheet reports that some 200 million people are living with coronary artery disease worldwide, and percutaneous coronary intervention is among the most frequently performed interventional procedures globally, with a drug-eluting stent implanted in the great majority of cases. The dominance of the segment rests on the strength of the clinical evidence base, which established that antiproliferative elution substantially reduces in-stent restenosis and target lesion revascularization relative to bare-metal stents, on mature and generally favorable reimbursement in the developed markets, and on the breadth of device sizes and designs available to treat the full range of coronary anatomy including bifurcations, small vessels, long lesions, and chronic total occlusions. Peripheral stenting constitutes the second segment and the faster-growing one, addressing the very large peripheral artery disease population that the American Heart Association places at some 200 million people globally, and it is served principally by self-expanding nitinol drug-eluting platforms developed for the femoropopliteal and below-the-knee territories where restenosis after conventional treatment has historically been high. Coronary stenting is expected to retain its dominant share throughout the forecast period, even as peripheral stenting grows faster.

By Scaffold

Dominant Subsegment: Cobalt-Chromium.

Dominant: Cobalt-Chromium ~ 46%

The cobalt-chromium segment accounted for a 46% share of the drug-eluting stents market in 2025. Cobalt-chromium dominates the scaffold structure because the alloy offers the most favorable combination of radial strength, radiopacity, and biocompatibility for coronary stent platforms, and because its high strength permits the ultrathin strut designs that define contemporary device performance. Thinner struts reduce the degree of vessel wall injury at deployment, improve deliverability through tortuous and calcified anatomy, lower the disturbance to blood flow that predisposes to thrombosis, and accelerate the endothelial healing that permits shorter dual antiplatelet regimens; these advantages have made cobalt-chromium the material of choice across the majority of the leading coronary drug-eluting stent families. The alloy also provides sufficient radiopacity for accurate fluoroscopic placement without the additional density required of earlier stainless steel designs. Platinum-chromium constitutes the second scaffold segment and an important one, offering greater radiopacity and enhanced conformability that some operators prefer for precise positioning and for treating complex anatomy. Nitinol serves a distinct and essential role as the self-expanding platform for peripheral applications, where its superelasticity and shape memory allow the stent to resist the external compression, bending, and torsion to which the femoropopliteal vessels are subjected, making it the standard for the peripheral segment. Other materials, including stainless steel and the bioresorbable polymers used in fully absorbable scaffolds, complete the structure. Cobalt-chromium is expected to retain its leading share throughout the forecast period.

Drug-Eluting Stents Market Region Analysis

Dominant Region: North America

Dominant: North America ~ 38% (Largest)

North America accounted for a 38% share of the global drug-eluting stents market in 2025. The region holds a dominant position globally, attributable to the high incidence of coronary artery disease, myocardial infarction, and their associated risk factors, combined with significant advancement in product development and regulatory approval, the presence of the leading market participants, and a well-established and advanced healthcare infrastructure. The National Institutes of Health reported that 20.5 million people in the United States were living with coronary artery disease, and data from the Centers for Disease Control and Prevention indicate that 805,000 people in the United States have a myocardial infarction each year on average, while the same source notes that about 47% of Americans have at least one of the three key risk factors of high blood cholesterol, high blood pressure, and smoking. The Canadian Institute for Health Information reported that 2.4 million Canadians were affected by heart disease, adding materially to the regional burden. Because cardiovascular disorders are rising in the region among middle-aged individuals as well as the elderly, demand for more effective diagnostic and treatment options is increasing significantly, fueling investment in innovative technologies. Product development activity further boosts the market, exemplified by the United States approval of a drug-coated balloon indicated to treat coronary in-stent restenosis. The presence of Abbott, Medtronic, and Boston Scientific with their strong distribution networks ensures widespread availability, and supportive reimbursement provides substantial growth opportunity. The region is expected to retain its dominant position throughout the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate in the drug-eluting stents market through 2034. The region is emerging as the principal growth engine of the market, propelled by an enormous and rapidly aging population, a sharply rising burden of coronary and peripheral artery disease driven by urbanization, dietary change, and the diabetes epidemic, and the rapid expansion of interventional cardiology capacity. Governments across the region are increasing healthcare budgets and investing in new hospitals and cardiac catheterization laboratories, particularly in China and India, which are expanding both the number of centers able to perform percutaneous intervention and the workforce of trained operators, converting a very large and previously undertreated disease burden into treated procedures. Rising disposable income, growing health awareness, and the gradual extension of insurance coverage and public reimbursement further increase the population able to access intervention. A distinctive feature of the region is the strength of its domestic manufacturers, with Chinese and Indian companies producing capable drug-eluting stents at price points suited to their home markets and increasingly exporting to other emerging economies, which accelerates volume adoption even as national price caps and volume-based procurement programs compress average selling prices and mean that unit growth outpaces value growth. China contributes the largest incremental volume, supported by a vast population and a substantial domestic industry; Japan combines a deeply aged population with advanced interventional practice and premium device adoption; and India represents a substantial long-term opportunity as access broadens. Regional growth is expected to exceed the global average across every segment.

Regional Commentary

North America

North America leads on value, innovation, and regulatory precedence, holding a 38% share in 2025. The region combines a high coronary and peripheral disease burden with advanced catheterization infrastructure, favorable reimbursement, high healthcare spending, and the presence of Abbott, Medtronic, and Boston Scientific. The National Institutes of Health report 20.5 million people in the United States living with coronary artery disease, the Centers for Disease Control and Prevention report 805,000 annual myocardial infarctions, and the Canadian Institute for Health Information reports 2.4 million Canadians affected by heart disease. The United States is the reference market for new scaffold, coating, and antiplatelet-labeling approvals. Near-term dynamics are shaped by ultrathin and biodegradable-polymer platforms, shortened dual antiplatelet therapy, peripheral expansion, and the outpatient migration of elective procedures.

Europe

Europe is a large and innovation-oriented market, supported by aging populations across Germany, France, Italy, the United Kingdom, and Spain that carry a high burden of coronary and peripheral artery disease, together with well-established interventional practice and generally supportive reimbursement across national health systems. European manufacturers are prominent innovators in biodegradable-polymer and polymer-free technology, and the region is frequently an early market for new platforms, exemplified by CE Mark approval of self-expanding drug-eluting stents for superficial femoral artery lesions. The European Union Medical Device Regulation has raised the evidentiary burden for new approvals and reshaped product availability in favor of manufacturers with regulatory scale, while competitive tendering exerts continued pressure on price.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by an enormous aging population, a rapidly rising burden of coronary and peripheral artery disease, the diabetes epidemic, and expanding catheterization capacity. Government investment in hospitals and cardiac centers, particularly in China and India, is converting untreated disease into procedures, and capable domestic manufacturers supply cost-effective devices that broaden access. China contributes the largest incremental volume and a substantial domestic industry, Japan combines deep aging with advanced practice and premium adoption, and India offers a large long-term opportunity. National price caps and volume-based procurement compress selling prices, so unit growth outpaces value growth, but regional expansion exceeds the global average across every segment.

Rest of World

The Rest of the World comprises the Middle East, Africa, and South America. Access is highly stratified. The Gulf Cooperation Council states and the larger South American markets, particularly Brazil, have invested in cardiac catheterization capacity and increasingly perform contemporary percutaneous intervention with premium drug-eluting devices, representing growing markets, while much of Africa lacks the catheterization laboratories, trained interventional workforce, and financing required, so a large share of obstructive coronary disease is never revascularized. Cost and limited reimbursement constrain premium device adoption in developing countries. Regional growth will be driven by investment in cardiac care infrastructure, the rising cardiovascular burden, government health initiatives, and lower-cost devices from regional and Asian manufacturers.

Drug-Eluting Stents Market Competitive Landscape

The global drug-eluting stents market is classified as Moderately Consolidated. A small group of large medical technology companies dominates the developed markets through established coronary stent franchises, extensive randomized clinical evidence, strong interventional cardiologist relationships, and global distribution, while capable regional manufacturers in Asia and Europe hold substantial and growing positions in their home and emerging markets on the strength of cost competitiveness. Competition centers on strut thickness and deliverability, coating technology and the duration of antiplatelet therapy the device permits, the depth of the clinical evidence base, and increasingly on price, and product launches, clinical trials, and tendering intensify rivalry. The competitive landscape is evaluated across the following dimensions:

  • Market concentration: Moderately consolidated, with a small group of large medical technology companies holding the majority of value in the developed markets through established coronary franchises, alongside capable regional manufacturers that hold substantial unit share in Asia and the emerging markets.
  • Leading players: Abbott leads with its everolimus-eluting XIENCE family, Medtronic competes through its Resolute and Onyx zotarolimus platforms, Boston Scientific through its platinum-chromium SYNERGY and Promus families, and BIOTRONIK and Terumo through bioabsorbable-polymer and ultrathin designs, with MicroPort, Meril, Biosensors, and Lepu contesting the emerging markets.
  • Geographic reach: The leading participants maintain global commercial and interventional-education organizations, while regional manufacturers including Meril, MicroPort, Lepu, and Sahajanand leverage cost advantages to serve large domestic markets and to expand across the emerging economies.
  • Product portfolio strength: Competitive advantage rests on breadth across scaffold, coating, and drug platforms together with a full range of sizes and lengths, since operators select a device for the specific anatomy and increasingly for the antiplatelet regimen it permits in high bleeding risk patients.
  • Pipeline strength: Development is concentrated in ultrathin-strut scaffolds, biodegradable-polymer and polymer-free coatings, shortened dual antiplatelet therapy labeling, dedicated peripheral and below-the-knee platforms, and bioresorbable vascular scaffolds.
  • Strategic partnerships: Collaboration spans large randomized clinical trial programs and registries conducted with academic and interventional centers, distribution agreements extending regional manufacturers into new geographies, and alliances integrating stents with intravascular imaging and physiology platforms.
  • M&A activity: Acquisition and consolidation have shaped the field, spanning the earlier absorption of pioneering stent innovators by the diversified leaders and continued transactions extending vascular intervention portfolios and adding drug-coated and peripheral capabilities.
  • Innovation focus: Innovation is shifting toward thinner and more deliverable scaffolds, coatings that permit shorter antiplatelet therapy, peripheral and below-the-knee applications, bioresorbable scaffolds, and the integration of artificial intelligence and intravascular imaging into stent sizing and optimization.
  • Regulatory standing: United States premarket approval and European Union Medical Device Regulation certification are decisive competitive credentials given the drug-device combination nature of these products, and the sequence of platform and antiplatelet-labeling approvals has become a principal axis of competition among the leaders.

Drug-Eluting Stents Market Recent Developmental Activities

In March 2024, Boston Scientific Corporation announced that it had received U.S. Food and Drug Administration approval for the AGENT Drug-Coated Balloon, indicated to treat coronary in-stent restenosis in patients with coronary artery disease. Strategic significance: the approval of the first drug-coated balloon for coronary in-stent restenosis in the United States addressed a persistent limitation of stenting, namely the treatment of restenosis within a previously implanted device, and extended the antiproliferative principle into a leave-nothing-behind adjacent modality that both complements and competes with repeat stenting.

Drug-Eluting Stents Market Segmentation

Drug-Eluting Stents Market Assessment by Type

  • Coronary Stenting
  • Peripheral Stenting

Drug-Eluting Stents Market Assessment by Scaffold

  • Platinum-Chromium
  • Cobalt-Chromium
  • Nitinol
  • Others

Drug-Eluting Stents Market Assessment by Coating

  • Polymer-Based Coating
  • Biodegradable
  • Non-Biodegradable
  • Polymer-Free Coating

Drug-Eluting Stents Market Assessment by Drug Type

  • Everolimus
  • Paclitaxel
  • Others

Drug-Eluting Stents Market Assessment by End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

Drug-Eluting Stents Market Assessment by Geography

  • North America
  • United States Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Canada Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Mexico Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Europe
  • France Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Germany Drug-Eluting Stents Market Size in USD million (2023-2034)
  • United Kingdom Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Italy Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Spain Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Rest of Europe Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Asia-Pacific
  • China Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Japan Drug-Eluting Stents Market Size in USD million (2023-2034)
  • India Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Australia Drug-Eluting Stents Market Size in USD million (2023-2034)
  • South Korea Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Rest of the World
  • Middle East Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Africa Drug-Eluting Stents Market Size in USD million (2023-2034)
  • South America Drug-Eluting Stents Market Size in USD million (2023-2034)

Key Takeaways from the Drug-Eluting Stents Market Report Study

  • Market size analysis for the current drug-eluting stent market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global drug-eluting stent market.
  • Various opportunities available for competitors in the drug-eluting stent market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current drug-eluting stent market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for drug-eluting stent market growth in the future?

Target audience who can benefit from this drug-eluting stent market report study

  • Radiofrequency ablation devices product providers
  • Research organizations and consulting companies
  • Radiofrequency ablation devices-related organizations, associations, forums, and other alliances.
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in drug-eluting stent
  • Various end-users who want to know more about the drug-eluting stent market and the latest technological developments in the drug-eluting stent market.

Frequently Asked Questions:

Q1. At what rate is the drug-eluting stents market expected to grow?

The global drug-eluting stents market is projected to grow at a compound annual growth rate of 7.88% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the drug-eluting stents market?

The global drug-eluting stents market was valued at USD 2.79 billion in 2025 and is projected to reach USD 5.53 billion by 2034.

Q3. Which region dominates the drug-eluting stents market?

North America dominated the drug-eluting stents market with a 38% share in 2025, driven by the high incidence of coronary artery disease and myocardial infarction and their risk factors, advanced healthcare infrastructure, favorable reimbursement, and the presence of Abbott, Medtronic, and Boston Scientific, with the National Institutes of Health reporting 20.5 million people in the United States living with coronary artery disease and the Centers for Disease Control and Prevention reporting 805,000 myocardial infarctions each year. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by an aging population, a rising cardiovascular burden, and expanding catheterization capacity across China, Japan, and India.

Table of Contents

1. Introduction

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Market Overview at a Glance

2. Executive Summary of Drug-Eluting Stents Market

  • 2.1. Key Highlights and Market Snapshot

3. Key Factors Impacting the Drug-Eluting Stents Market

  • 3.1. Market Drivers
    • 3.1.1. Increasing Incidence of Cardiovascular Disorders
    • 3.1.2. Growing Instances of Lifestyle-Related Disorders
    • 3.1.3. Increasing Preference for Minimally Invasive Procedures
    • 3.1.4. Rising Product Development and Technological Advancement
  • 3.2. Market Restraints
    • 3.2.1. Risks and Complications Associated with Drug-Eluting Stents
    • 3.2.2. Stringent Regulatory Approval Process
    • 3.2.3. Pricing Pressure and Competitive Substitution
  • 3.3. Market Opportunities
    • 3.3.1. Development of Bioresorbable Vascular Scaffolds
    • 3.3.2. Integrating AI and Robotics for Stent Placement

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1. The United States
  • 5.2. Europe
  • 5.3. Japan
  • 5.4. China

6. Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Drug-Eluting Stents Market Assessment

  • 7.1. By Type
    • 7.1.1. Coronary Stenting
    • 7.1.2. Peripheral Stenting
  • 7.2. By Scaffold
    • 7.2.1. Platinum-Chromium
    • 7.2.2. Cobalt-Chromium
    • 7.2.3. Nitinol
    • 7.2.4. Others
  • 7.3. By Coating
    • 7.3.1. Polymer-Based Coating
      • 7.3.1.1. Biodegradable
      • 7.3.1.2. Non-Biodegradable
    • 7.3.2. Polymer-Free Coating
  • 7.4. By Drug Type
    • 7.4.1. Everolimus
    • 7.4.2. Paclitaxel
    • 7.4.3. Others
  • 7.5. By End-User
    • 7.5.1. Hospitals
    • 7.5.2. Ambulatory Surgical Centers
    • 7.5.3. Specialty Clinics
  • 7.6. By Geography
    • 7.6.1. North America
      • 7.6.1.1. United States Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.1.2. Canada Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.1.3. Mexico Drug-Eluting Stents Market Size in USD million (2023-2034)
    • 7.6.2. Europe
      • 7.6.2.1. France Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.2.2. Germany Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.2.3. United Kingdom Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.2.4. Italy Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.2.5. Spain Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.2.6. Rest of Europe Drug-Eluting Stents Market Size in USD million (2023-2034)
    • 7.6.3. Asia-Pacific
      • 7.6.3.1. China Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.3.2. Japan Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.3.3. India Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.3.4. Australia Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.3.5. South Korea Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.3.6. Rest of Asia-Pacific Drug-Eluting Stents Market Size in USD million (2023-2034)
    • 7.6.4. Rest of the World
      • 7.6.4.1. Middle East Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.4.2. Africa Drug-Eluting Stents Market Size in USD million (2023-2034)
      • 7.6.4.3. South America Drug-Eluting Stents Market Size in USD million (2023-2034)

8. Drug-Eluting Stents Market Competitive Landscape

  • 8.1. Competitive Analysis
  • 8.2. Company Share Analysis (Premium Offering)

9. Drug-Eluting Stents Market Startup Funding and Investment Trends

10. Company and Product Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Company Overview
    • 10.1.2. Company Snapshot
    • 10.1.3. Financial Overview
    • 10.1.4. Product Listing
    • 10.1.5. Strategic Initiatives / Entropy
  • 10.2. Medtronic plc
    • 10.2.1. Company Overview
    • 10.2.2. Company Snapshot
    • 10.2.3. Financial Overview
    • 10.2.4. Product Listing
    • 10.2.5. Strategic Initiatives / Entropy
  • 10.3. Boston Scientific Corporation
    • 10.3.1. Company Overview
    • 10.3.2. Company Snapshot
    • 10.3.3. Financial Overview
    • 10.3.4. Product Listing
    • 10.3.5. Strategic Initiatives / Entropy
  • 10.4. BIOTRONIK SE & Co. KG
    • 10.4.1. Company Overview
    • 10.4.2. Company Snapshot
    • 10.4.3. Financial Overview
    • 10.4.4. Product Listing
    • 10.4.5. Strategic Initiatives / Entropy
  • 10.5. Terumo Corporation
    • 10.5.1. Company Overview
    • 10.5.2. Company Snapshot
    • 10.5.3. Financial Overview
    • 10.5.4. Product Listing
    • 10.5.5. Strategic Initiatives / Entropy
  • 10.6. MicroPort Scientific Corporation
    • 10.6.1. Company Overview
    • 10.6.2. Company Snapshot
    • 10.6.3. Financial Overview
    • 10.6.4. Product Listing
    • 10.6.5. Strategic Initiatives / Entropy
  • 10.7. B. Braun Melsungen AG
    • 10.7.1. Company Overview
    • 10.7.2. Company Snapshot
    • 10.7.3. Financial Overview
    • 10.7.4. Product Listing
    • 10.7.5. Strategic Initiatives / Entropy
  • 10.8. Meril Life Sciences Pvt. Ltd.
    • 10.8.1. Company Overview
    • 10.8.2. Company Snapshot
    • 10.8.3. Financial Overview
    • 10.8.4. Product Listing
    • 10.8.5. Strategic Initiatives / Entropy
  • 10.9. Biosensors International Group Ltd.
    • 10.9.1. Company Overview
    • 10.9.2. Company Snapshot
    • 10.9.3. Financial Overview
    • 10.9.4. Product Listing
    • 10.9.5. Strategic Initiatives / Entropy
  • 10.10. Lepu Medical Technology Co. Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Company Snapshot
    • 10.10.3. Financial Overview
    • 10.10.4. Product Listing
    • 10.10.5. Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Global Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Table 2: Global Drug-Eluting Stents Market Size by Type in USD million (2023-2034)
  • Table 3: Global Drug-Eluting Stents Market Size by Scaffold in USD million (2023-2034)
  • Table 4: Global Drug-Eluting Stents Market Size by Coating in USD million (2023-2034)
  • Table 5: Global Drug-Eluting Stents Market Size by Drug Type in USD million (2023-2034)
  • Table 6: Global Drug-Eluting Stents Market Size by End-User in USD million (2023-2034)
  • Table 7: Drug-Eluting Stents Market Size in North America in USD million (2023-2034)
  • Table 8: Drug-Eluting Stents Market Size in the United States in USD million (2023-2034)
  • Table 9: Drug-Eluting Stents Market Size in Canada in USD million (2023-2034)
  • Table 10: Drug-Eluting Stents Market Size in Mexico in USD million (2023-2034)
  • Table 11: Drug-Eluting Stents Market Size in Europe in USD million (2023-2034)
  • Table 12: Drug-Eluting Stents Market Size in France in USD million (2023-2034)
  • Table 13: Drug-Eluting Stents Market Size in Germany in USD million (2023-2034)
  • Table 14: Drug-Eluting Stents Market Size in the United Kingdom in USD million (2023-2034)
  • Table 15: Drug-Eluting Stents Market Size in Italy in USD million (2023-2034)
  • Table 16: Drug-Eluting Stents Market Size in Spain in USD million (2023-2034)
  • Table 17: Drug-Eluting Stents Market Size in the Rest of Europe in USD million (2023-2034)
  • Table 18: Drug-Eluting Stents Market Size in Asia-Pacific in USD million (2023-2034)
  • Table 19: Drug-Eluting Stents Market Size in China in USD million (2023-2034)
  • Table 20: Drug-Eluting Stents Market Size in Japan in USD million (2023-2034)
  • Table 21: Drug-Eluting Stents Market Size in India in USD million (2023-2034)
  • Table 22: Drug-Eluting Stents Market Size in Australia in USD million (2023-2034)
  • Table 23: Drug-Eluting Stents Market Size in South Korea in USD million (2023-2034)
  • Table 24: Drug-Eluting Stents Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Table 25: Drug-Eluting Stents Market Size in the Rest of the World in USD million (2023-2034)
  • Table 26: Drug-Eluting Stents Market Size in the Middle East in USD million (2023-2034)
  • Table 27: Drug-Eluting Stents Market Size in Africa in USD million (2023-2034)
  • Table 28: Drug-Eluting Stents Market Size in South America in USD million (2023-2034)
  • Table 29: Drug-Eluting Stents Market Competitive Landscape
  • Table 30: Drug-Eluting Stents Market Startup Funding and Investment Trends

List of Figures

  • Figure 1: Drug-Eluting Stents Market Drivers
  • Figure 2: Drug-Eluting Stents Market Restraints
  • Figure 3: Drug-Eluting Stents Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis of the Drug-Eluting Stents Market (the United States)
  • Figure 6: Regulatory Analysis of the Drug-Eluting Stents Market (Europe)
  • Figure 7: Regulatory Analysis of the Drug-Eluting Stents Market (Japan)
  • Figure 8: Regulatory Analysis of the Drug-Eluting Stents Market (China)
  • Figure 9: Porter's Five Forces Analysis of the Drug-Eluting Stents Market
  • Figure 10: Competitive Analysis of the Drug-Eluting Stents Market
  • Figure 11: Global Drug-Eluting Stents Market Size in USD million (2023-2034)
  • Figure 12: Global Drug-Eluting Stents Market Size by Type in USD million (2023-2034)
  • Figure 13: Global Drug-Eluting Stents Market Size by Scaffold in USD million (2023-2034)
  • Figure 14: Global Drug-Eluting Stents Market Size by Coating in USD million (2023-2034)
  • Figure 15: Global Drug-Eluting Stents Market Size by Drug Type in USD million (2023-2034)
  • Figure 16: Global Drug-Eluting Stents Market Size by End-User in USD million (2023-2034)
  • Figure 17: Drug-Eluting Stents Market Size in North America in USD million (2023-2034)
  • Figure 18: Drug-Eluting Stents Market Size in the United States in USD million (2023-2034)
  • Figure 19: Drug-Eluting Stents Market Size in Canada in USD million (2023-2034)
  • Figure 20: Drug-Eluting Stents Market Size in Mexico in USD million (2023-2034)
  • Figure 21: Drug-Eluting Stents Market Size in Europe in USD million (2023-2034)
  • Figure 22: Drug-Eluting Stents Market Size in France in USD million (2023-2034)
  • Figure 23: Drug-Eluting Stents Market Size in Germany in USD million (2023-2034)
  • Figure 24: Drug-Eluting Stents Market Size in the United Kingdom in USD million (2023-2034)
  • Figure 25: Drug-Eluting Stents Market Size in Italy in USD million (2023-2034)
  • Figure 26: Drug-Eluting Stents Market Size in Spain in USD million (2023-2034)
  • Figure 27: Drug-Eluting Stents Market Size in the Rest of Europe in USD million (2023-2034)
  • Figure 28: Drug-Eluting Stents Market Size in Asia-Pacific in USD million (2023-2034)
  • Figure 29: Drug-Eluting Stents Market Size in China in USD million (2023-2034)
  • Figure 30: Drug-Eluting Stents Market Size in Japan in USD million (2023-2034)
  • Figure 31: Drug-Eluting Stents Market Size in India in USD million (2023-2034)
  • Figure 32: Drug-Eluting Stents Market Size in Australia in USD million (2023-2034)
  • Figure 33: Drug-Eluting Stents Market Size in South Korea in USD million (2023-2034)
  • Figure 34: Drug-Eluting Stents Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Figure 35: Drug-Eluting Stents Market Size in the Rest of the World in USD million (2023-2034)
  • Figure 36: Drug-Eluting Stents Market Size in the Middle East in USD million (2023-2034)
  • Figure 37: Drug-Eluting Stents Market Size in Africa in USD million (2023-2034)
  • Figure 38: Drug-Eluting Stents Market Size in South America in USD million (2023-2034)
  • Figure 39: Drug-Eluting Stents Market Competitive Landscape
  • Figure 40: Drug-Eluting Stents Market Startup Funding and Investment Trends